公开(公告)号：US6033687A

公开(公告)日：2000-03-07

申请号：US287904

申请日：1999-04-07

申请人： Grant W. Heinicke ,  Angelo Lepore ,  Angelo M. Morella

发明人： Grant W. Heinicke ,  Angelo Lepore ,  Angelo M. Morella

IPC分类号： A61K9/50 ,  A61K9/54 ,  A61K31/554

CPC分类号： A61K9/5078 ,  A61K31/554 ,  A61K9/5084

摘要： A controlled absorption diltiazem pellet formulation for oral administration comprises a core having diltiazem or a pharmaceutically acceptable salt thereof as the active ingredient. The core is surrounded by a coating which has only a single layer which is comprised of a relatively major proportion of talc and relatively minor proportion of sodium lauryl sulfate admixed with a minor proportion of a pharmaceutically acceptable film-forming, first polymer permeable to water and diltiazem, and a major proportion of a pharmaceutically acceptable film-forming, second polymer that is less permeable to water and diltiazem than the first polymer. The core and the coating layer both exclude organic acids. The composition of the coating layer as well as the proportion of core to coating layer are effective to permit release of the diltiazem allowing controlled absorption following oral administration. By combining short lag and long lag pellets into a single formulation, the release of diltiazem is controlled over a twenty four hour period.

摘要翻译： 用于口服给药的受控吸收性地尔硫卓丸剂制剂包括具有地尔硫卓或其药学上可接受的盐作为活性成分的核心。 核心被仅由单一层组成的涂层包围，该层由相​​对较大比例的滑石和相对较少比例的十二烷基硫酸钠组成，其中少量的可药用成膜的第一聚合物可渗透水分， 地尔硫卓和大部分可药用成膜的第二聚合物，其比第一聚合物对水和地尔硫卓渗透性较差。 核心和涂层都排除有机酸。 涂层的组成以及芯与包衣层的比例对于允许释放硫酸盐是有效的，允许经口给药后受控吸收。 通过将短滞后和长滞后丸混合成单一制剂，地尔硫卓的释​​放可控制在二十四小时内。

公开(公告)号：US07067151B1

公开(公告)日：2006-06-27

申请号：US09606629

申请日：2000-06-29

申请人： Grant W. Heinicke ,  Angelo Lepore ,  Angelo M. Morella

发明人： Grant W. Heinicke ,  Angelo Lepore ,  Angelo M. Morella

IPC分类号： A61K9/54

CPC分类号： A61K9/5078 ,  A61K9/5084 ,  A61K31/554

摘要： A controlled absorption diltiazem pellet formulation for oral administration comprises a core having diltiazem or a pharmaceutically acceptable salt thereof as the active ingredient. The core is surrounded by a coating which has only a single layer which is comprised of a relatively major proportion of talc and relatively minor proportion of sodium lauryl sulfate admixed with a minor proportion of a pharmaceutically acceptable film-forming, first polymer permeable to water and diltiazem, and a major proportion of a pharmaceutically acceptable film-forming, second polymer that is less permeable to water and diltiazem than the first polymer. The core and the coating layer both exclude organic acids. The composition of the coating layer as well as the proportion of core to coating layer are effective to permit release of the diltiazem allowing controlled absorption following oral administration. By combining short lag and long lag pellets into a single formulation, the release of diltiazem is controlled over a twenty four hour period.

公开(公告)号：US06214385B1

公开(公告)日：2001-04-10

申请号：US09447642

申请日：1999-11-23

申请人： Grant W. Heinicke ,  Angelo Lepore ,  Angelo M. Morella

发明人： Grant W. Heinicke ,  Angelo Lepore ,  Angelo M. Morella

IPC分类号： A61K954

CPC分类号： A61K9/5078 ,  A61K9/5084 ,  A61K31/554

摘要： A controlled absorption diltiazem pellet formulation for oral administration comprises a core having diltiazem or a pharmaceutically acceptable salt thereof as the active ingredient. The core is surrounded by a coating which has only a single layer which is comprised of a relatively major proportion of talc and relatively minor proportion of sodium lauryl sulfate admixed with a minor proportion of a pharmaceutically acceptable film-forming, first polymer permeable to water and diltiazem, and a major proportion of a pharmaceutically acceptable film-forming, second polymer that is less permeable to water and diltiazem than the first polymer. The core and the coating layer both exclude organic acids. The composition of the coating layer as well as the proportion of core to coating layer are effective to permit release of the diltiazem allowing controlled absorption following oral administration. By combining short lag and long lag pellets into a single formulation, the release of diltiazem is controlled over a twenty four hour period.

摘要翻译： 用于口服给药的受控吸收性地尔硫卓丸剂制剂包括具有地尔硫卓或其药学上可接受的盐作为活性成分的核心。 核心被仅由单一层组成的涂层包围，该层由相​​对较大比例的滑石和相对较少比例的十二烷基硫酸钠组成，其中少量的可药用成膜的第一聚合物可渗透水分， 地尔硫卓和大部分可药用成膜的第二聚合物，其比第一聚合物对水和地尔硫卓渗透性较差。 核心和涂层都排除有机酸。 涂层的组成以及芯与包衣层的比例对于允许释放硫酸盐是有效的，允许经口给药后受控吸收。 通过将短滞后和长滞后丸混合成单一制剂，地尔硫卓的释​​放可控制在二十四小时内。